Table 4. Genes that were critical nodes in the sub-network.
| Critical genes | Number of sub-networks where critical |
|---|---|
| TP53* | 20 |
| AKT1* | 20 |
| PCNA* | 17 |
| SRC* | 15 |
| INS-IGF2 | 12 |
| SF3A2 | 10 |
| BIRC5 | 10 |
| DKC1 | 9 |
| ESR1* | 8 |
| BUB1 | 7 |
| BRCA1 | 7 |
| RPL11 | 7 |
| YBX1* | 7 |
| RPS16* | 6 |
| GRB2* | 6 |
| POLR2H | 6 |
| HNRNPK | 5 |
| MDM2 | 5 |
| CASP3 | 5 |
| POLR2A* | 5 |
| CDK5 | 5 |
| SP1 | 5 |
A node is included if the gene appears in at least 20% of experimental sub-networks (5 out of 21). These nodes have a critical role in several sub-networks and may be key cryptic genetic factors in metformin’s signaling network. *indicates genes which have known carcinogenic mutations that could significantly alter the networks.